首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1634217

全球射頻消融設備市場 - 2025 - 2033

Global Radiofrequency Ablation Devices Market - 2025 - 2033

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球射頻消融設備市場規模達56.3億美元，預計2033年將達到135.4億美元，2025-2033年預測期間複合年成長率為10.7%。

射頻消融（RFA）是一種微創醫療手術，透過高頻交流電產生熱量，然後用它來消除或消融體內的某些組織。此手術廣泛應用於各種醫學專業，包括介入放射學和心臟病學，特別有助於治療腫瘤、心律不整和慢性疼痛。該方法包括將一根細針或導管引入所需位置，並施加射頻輻射以引起局部加熱。這種熱會破壞異常組織，削弱或消除其功能。

RFA 具有廣泛的應用。在腫瘤學中，它被用來消滅肝臟、肺和腎臟等器官中的惡性腫瘤。在心臟病學中，射頻消融用於解決導致心律不整的心臟電路故障。它也用於疼痛管理，以破壞導致慢性疼痛疾病（包括關節炎和下背痛）的神經訊號。 RFA 的多功能性使其成為現代醫學的重要工具，為患者提供侵入性最小的優質醫療替代方案。

市場動態：

驅動程式和限制

對射頻消融設備的需求不斷增加

對射頻消融設備的需求不斷成長預計將成為全球射頻消融設備市場成長的重要因素。由於慢性病盛行率上升、技術進步、對微創外科手術的日益偏好以及最近的推出和批准，對體內給藥裝置的需求不斷增加。

隨著癌症、心血管疾病和慢性疼痛等慢性疾病變得越來越普遍，醫療保健提供者正在尋找有效的治療替代方案，以減少患者的痛苦並縮短復原時間。例如，根據美國心臟學會基金會的數據，高收縮壓對年齡標準化 CVD 傷殘調整生命年 (DALY) 的貢獻最大，全世界每 10 萬人中有 2,564.9 人患有高收縮壓。

RFA 是一種誘人的解決方案，因為它能夠精確定位異常組織，同時保持鄰近的健康結構。此功能在腫瘤學中特別有用，RFA 用於治療實體腫瘤，為可能不適合標準手術的患者提供了可行的選擇。該市場也受到技術進步的推動，這些進步提高了這些設備在各種醫療環境中的功效、安全性和可用性。隨著醫療保健格局的變化，RFA 技術的進步使這些設備更容易使用和有效地治療各種疾病，包括慢性病和惡性腫瘤，這些疾病在全球範圍內變得越來越普遍。 RFA 技術最重要的進步之一是引入多針電極裝置。這些方法可以實現更精確的組織定位，使醫生能夠以更高的精度治療更大的區域，同時減少對附近健康組織的損害。這種準確性在腫瘤學中至關重要，在保留健康結構的同時正確消融腫瘤細胞的能力對患者的治療結果有重大影響。

此外，RFA 設備中包含的即時監控功能可以為臨床醫生在手術過程中提供即時回饋。此功能可更好地控制能量傳遞過程，確保在整個治療過程中保持適當的溫度，從而提高安全性和有效性。最近推出並批准了射頻消融設備。例如，2024 年 10 月，波士頓科學公司宣布用於治療陣發性心房顫動 (AF) 的具有導航功能的 FARAWAVE NAV 消融導管已獲得 FDA 批准，以及新 FARAVIEW 軟體的 FDA 510(k) 許可，它將與FARAPULSE 脈衝場消融(PFA) 系統結合使用，為心臟消融手術提供可視化。這些技術僅與波士頓科學公司現有的心臟測繪技術和該公司的最新產品 OPAL HDx 測繪系統相容。

與射頻消融裝置相關的副作用和併發症

與射頻消融設備相關的副作用和併發症等因素預計將阻礙全球射頻消融設備市場。 RFA 通常被認為是一種安全且侵入性極小的治療方法，但它並非沒有潛在危險。接受 RFA 的患者可能會出現多種副作用，包括不適、水腫和注射部位附近的過敏。這些症狀可能表現為灼熱感或麻木，類似於曬傷，並且可能在手術後持續數天甚至數週。這種不適感可能會導致患者不滿並不願意在未來繼續接受這種治療，進而影響整體市場的接受度和成長。此外，儘管不常見，但在 RFA 操作期間或之後可能會出現更嚴重的問題。注射部位感染、神經和血管損傷以及出血都是可能的併發症。

Radiofrequency ablation (RFA) is a minimally invasive medical procedure that generates heat from high-frequency alternating current and then uses it to eliminate or ablate certain tissues in the body. This procedure is widely used in a variety of medical specialties, including interventional radiology and cardiology, and is especially helpful in treating tumors, cardiac arrhythmias, and chronic pain. The method involves introducing a tiny needle or catheter into the desired location and applying radiofrequency radiation to induce localized heating. This heat causes the destruction of aberrant tissue, diminishing or eliminating its function.

RFA has a wide variety of applications. In oncology, it is used to destroy malignancies in organs like the liver, lungs, and kidneys. In cardiology, RFA is used to address faulty electrical circuits in the heart that cause arrhythmia. It is also used in pain management to disrupt nerve signals that cause chronic pain diseases including arthritis and lower back pain. RFA's versatility makes it an essential instrument in modern medicine, providing patients with superior healthcare alternatives that are minimally intrusive.

Market Dynamics: Drivers & Restraints

Increasing demand for radiofrequency ablation devices

The increasing demand for radiofrequency ablation devices is expected to be a significant factor in the growth of the global radiofrequency ablation devices market. The demand for on-body drug delivery devices is increasing owing to the rising prevalence of chronic diseases, technological advancements, growing preference for minimally invasive surgical procedures, and recent launches and approvals.

As chronic disorders like cancer, cardiovascular disease, and chronic pain become more common, healthcare providers are looking for efficient treatment alternatives that will reduce patient misery and recovery time. For instance, according to the American College of Cardiology Foundation, High systolic blood pressure contributed the most to age-standardized CVD disability-adjusted life years (DALYs), with 2,564.9 per 100,000 people worldwide.

RFA is an enticing solution because it enables precision targeting of aberrant tissues while maintaining adjacent healthy structures. This feature is especially useful in oncology, where RFA is used to treat solid tumors, giving it a viable option for patients who may not be candidates for standard surgery. The market is also driven by technological advancements that improve the efficacy, safety, and usability of these devices in a variety of medical settings. As the healthcare landscape changes, advances in RFA technology make these devices more accessible and effective for treating a wide range of ailments, including chronic diseases and malignancies, which are becoming more common worldwide. One of the most significant advances in RFA technology has been the introduction of multi-needle electrode devices. These methods enable more precise tissue targeting, allowing doctors to treat larger areas with higher accuracy while reducing damage to healthy tissues nearby. This accuracy is critical in oncology, where the ability to properly ablate tumor cells while conserving healthy structures has a substantial impact on patient outcomes.

Furthermore, the inclusion of real-time monitoring capabilities in RFA devices gives clinicians immediate feedback during operations. This feature provides greater control over the energy delivery process, ensuring that the proper temperature is maintained throughout the treatment, improving both safety and effectiveness. There are recent launches and approvals of radiofrequency ablation devices. For instance, in October 2024, Boston Scientific Corporation announced that the navigation-enabled FARAWAVE NAV Ablation Catheter for the treatment of paroxysmal atrial fibrillation (AF) has received FDA approval, as well as FDA 510(k) clearance for the new FARAVIEW Software, which will be used in conjunction with the FARAPULSE Pulsed Field Ablation (PFA) System to provide visualization for cardiac ablation procedures. These technologies are only compatible with Boston Scientific's existing cardiac mapping technology and the company's newest product, the OPAL HDx Mapping System.

Side effects and complications associated with radiofrequency ablation devices

Factors such as side effects and complications associated with radiofrequency ablation devices are expected to hamper the global radiofrequency ablation devices market. RFA is generally regarded as a safe and minimally intrusive therapy, however, it is not without potential hazards. Patients undergoing RFA may have a variety of side effects, including discomfort, edema, and hypersensitivity near the injection site. These symptoms might emerge as burning sensations or numbness, similar to sunburn, and may last for days or even weeks after the surgery. Such discomfort may cause patient discontent and reluctance to pursue this treatment in the future, affecting overall market acceptance and growth. Furthermore, more significant problems, albeit uncommon, can arise during or following the RFA operation. Infections at the injection site, nerve and blood vessel injury, and bleeding are all possible complications.

Segment Analysis

The global radiofrequency ablation devices market is segmented based on component type, application, end-user, and region.

Capital equipment segment is expected to dominate the global radiofrequency ablation devices market share

The capital equipment segment is anticipated to dominate the global radiofrequency ablation devices market owing to its increasing prevalence of chronic diseases, growing need for effective treatment options, technological advancements, and recent launches and approvals. This expansion relies heavily on capital equipment, which includes expensive goods such as radiofrequency generators and sophisticated ablation devices. These technologies improve both therapy efficacy and patient outcomes, making them indispensable in modern medical procedures. Furthermore, the capital equipment segment benefits from the continuing trend of technological innovation in healthcare. As hospitals and clinics invest in modern RFA systems, they become better prepared to manage complex cases requiring precision and dependability.

Technological advancements in RFA devices have resulted in increased precision and control during operations. Modern RFA systems use modern electrosurgical generators to deliver heat energy more precisely, allowing for targeted tissue destruction while protecting surrounding healthy tissue. These advances not only improve treatment outcomes but also cut recovery times, making RFA a more compelling alternative for patients. There are recent launches and approvals which are manufactured using advanced technology.

For instance, in October 2024, Abbott announced that it has completed two major milestones to support the company's growing suite of pulsed-field ablation (PFA) solutions in electrophysiology, early enrollment in the VOLT-AF IDE Study supporting the Volt PFA System, and the launch of the FOCALFLEX trial to assess the company's TactiFlex Duo Ablation Catheter, Sensor Enabled (SE), which will be used in the treatment of patients with paroxysmal atrial fibrillation. These two trials offer major benefits for the future of two Abbott PFA catheters, which are being developed as critical tools for clinicians treating patients with irregular heart rhythms like as atrial fibrillation (AFib).

Geographical Analysis

North America is expected to hold a significant position in the global radiofrequency ablation devices market share

North America will likely account for a significant share of the global radiofrequency ablation devices market, owing to its advanced healthcare infrastructure, increasing investments, a high prevalence of chronic diseases, technological advancements, and recent launches and approvals. This upward trend is primarily attributable to the increasing number of people suffering from chronic ailments such as cancer, arthritis, and cardiovascular disease.

For instance, according to the National Institute of Health, approximately 82.6 million people in the United States suffer from one or more forms of cardiovascular disease (CVD). Coronary heart disease (CHD), stroke, hypertension, and congestive heart failure are among the most common forms of cardiovascular disease. CHD affects an estimated 16.3 million Americans aged 20 and older, accounting for a 7% prevalence. The prevalence for men is 8.3 percent, while for women it is 6.1 percent. About 7 million Americans aged 20 and up have experienced a stroke. Each year, around 610,000 people have their first stroke, with another 185,000 experiencing a recurrence. Approximately 87 percent of all strokes are ischemic, with 10% caused by intracerebral hemorrhage and 3% by subarachnoid hemorrhage. Cardiovascular disease, diabetes, and autoimmune disorders are becoming more prevalent in the population. This frightening trend emphasizes the critical need for improved medical technologies capable of providing appropriate therapies for individuals suffering from chronic diseases.

The development of multi-needle electrodes and enhanced visualization techniques is one of the important technological advances that is driving the market. These advancements give more precision during surgeries, allowing medical professionals to target specific locations more effectively while limiting injury to neighboring tissues. Real-time imaging integration improves the visibility of anatomical features, which is critical for successful therapies. As a result, patients experience better outcomes and shorter recovery times, making RFA a better choice for both physicians and patients.

The market expansion is being driven by increasing expenditures on healthcare and a determined push to adopt modern medical technology, which is critical for tackling the growing prevalence of chronic diseases such as cancer and cardiovascular ailments.

The increased recognition of the benefits of radiofrequency ablation techniques is a major driver of this investment boom. As healthcare providers strive to improve patient outcomes while reducing costs, RFA technology investments have become a top priority. Hospitals and clinics are rapidly spending money to acquire cutting-edge RFA devices with improved precision and safety features. For instance, in June 2024, Kardium, the developer of a pulsed field ablation and mapping system for atrial fibrillation (AFib), announced that it has raised $104 million in the latest fundraising round to assist the firm prepare for commercialization. The funds will be used to finish Kardium's Pulsar clinical study, which is required to secure regulatory approval for their Globe mapping and ablation device. In addition, the company intends to increase its production team and capacity, as well as establish clinical support and commercial teams.

Asia Pacific is growing at the fastest pace in the global radiofrequency ablation devices market

The Asia Pacific region is emerging as the fastest-growing market for radiofrequency ablation devices, owing to a combination of demographic trends, increased healthcare investment, technological advancements, recent launches, and a rising number of chronic diseases. This increase is largely due to the increased prevalence of disorders like as cardiovascular disease (CVDs) and cancer, which require effective treatment alternatives such as RFA.

For instance, according to the National Institute of Health, Coronary heart disease prevalence rates in India have been calculated throughout the last several decades, ranging from 1.6% to 7.4% in rural populations and 1% to 13.2% in metropolitan areas. This disturbing development highlights the critical need for modern medical therapies, such as RFA, to successfully manage these chronic illnesses. The rising prevalence of chronic diseases in Asia Pacific is exacerbated by demographic changes, notably an aging population.

Competitive Landscape

The major global players in the global radiofrequency ablation devices market include Boston Scientific Corporation, Medtronic, Stryke, Abbott, Smith+Nephew, Johnson & Johnson Services, Inc., AngioDynamic, Hologic, Inc., Arthrex, Inc., STARmed America among others.

Emerging Players

Ananya Health, Sedivention, and Field Medical among others

Key Developments

In December 2023, Ajax Health announced the establishment of Cortex, a new company focused on developing comprehensive ablation technology for treating atrial fibrillation (AFib), with an initial funding of $90 million. This investment round was led by prominent firms KKR and Hellman & Friedman, along with contributions from other investors, including AI Life Sciences. The funding will support Cortex's mission to create advanced diagnostic and pulsed-field ablation (PFA) catheters, which are essential for improving treatment outcomes for patients suffering from AFib.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global radiofrequency ablation devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Component Type
3.2. Snippet by Application
3.3. Snippet by End-User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. Increasing Demand for Radiofrequency Ablation Devices
- 4.1.3. Restraints
- 4.1.4. Side Effects and Complications Associated with Radiofrequency Ablation Devices
- 4.1.5. Opportunity
- 4.1.6. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Component Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 6.1.2. Market Attractiveness Index, By Component Type
6.2. Disposable equipment*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Capital equipment
6.4. Reusable equipment

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Surgical oncology*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Cardiology & cardiac rhythm management
7.4. Cosmetology
7.5. Gynecology
7.6. Pain management

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Ambulatory Surgical Centers
8.4. Others

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. Boston Scientific Corporation*
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Medtronic
11.3. Stryker
11.4. Abbott
11.5. Smith+Nephew
11.6. Johnson & Johnson Services, Inc.
11.7. AngioDynamic
11.8. Hologic, Inc.
11.9. Arthrex, Inc.
11.10. STARmed America

LIST NOT EXHAUSTIVE